Regularly taking prescription painkillers, also known as opioids, is associated with a higher risk of erectile dysfunction (ED) in men, according to a study published online today in the journal Spine.
[More]
Older adults living with chronic pain, as well as their families and carers, have the opportunity to give their views to health experts at the University of Greenwich.
[More]
Patients coping with chronic pain should also be evaluated for anxiety disorders, according to new research published in General Hospital Psychiatry.
[More]
Interspinous spacer implantation-a less-invasive alternative surgical option for spinal stenosis-has a lower complication rate than spinal fusion, reports a study in the May 1 issue of Spine The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
[More]
A study comparing low-income people in Oregon who received access to Medicaid over the past two years with those who did not, found that those on Medicaid visited doctors and hospitals more often, suffered less from depression and were more financially secure.
[More]
A clinical trial being conducted at the University of British Columbia, sponsored by Active-O, is currently recruiting patients suffering from lower back pain caused by a contained herniated disc to investigate a new, non-surgical treatment.
[More]
Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).
[More]
Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.
[More]
Rates of premature mortality in the UK have been falling steadily, but the pace of decline is not as fast as in many other high-income countries, such as Australia. In that sense, the UK lags behind.
[More]
DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC ("DJOFL"), for the first quarter ended March 30, 2013.
[More]
Auricular point acupressure may have potential for the treatment of chronic low back pain, findings from a feasibility study show.
[More]
Researchers at the University of Huddersfield have published a research paper that focuses on the social factors involved in back pain sufferers returning to work, to give a wider context to the medical factors that are often considered.
[More]
An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.
[More]
FIK, Tecnalia and BTS launch a belt to prevent lower back pain problems and provide rehabilitation at home and at work. The Lumbia device can be used for patient´s assessment, and for therapy during postural re-education.
[More]
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.
[More]
GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).
[More]
Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).
[More]
Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.
[More]
More women than men develop chronic low back pain and sciatica. The explanation may lie with a gene variant that plays into the body's pain regulation.
[More]
The shape of an individual's spinal column may predict his or her risk for nursing home admission or need of home assistance in old age, according to a new article published online in the Journals of Gerontology Series A: Biological Sciences and Medical Sciences.
[More]